Is niraparib a targeted drug?

Niraparib (Niraparib) is a targeted cancer drug called a PARP inhibitor. It is also known as Zejula. This is a treatment for certain types of ovarian, fallopian tube, or primary peritoneal cancer. PARP is a protein that helps healthy and unhealthy cells repair damaged DNA. DNA stands for deoxyribonucleic acid. This is the core genetic code of all animal and plant cells. It controls all cell activities. Cancer cells rely on PARP proteins to keep their DNA healthy so they can continue to grow and divide. Niraparib stops the PARP protein from working, so the cancer cells die.

Niraparib is available as capsules (100 mg) for oral administration. The dosage is 2 or 3 capsules once daily, depending on the patient's weight, platelet count and whether the cancer has returned after previous treatment. Treatment should continue as long as the patient benefits from it. If a patient experiences certain side effects, the doctor may interrupt treatment or reduce the dose. The drug niraparib is only available by prescription, and treatment should be started and supervised by a doctor experienced in the use of cancer drugs.

NiraparibThe original drug has been launched in China and is included in medical insurance, but reimbursement is limited to eligible patients. The price of a common specification100mg*30 capsules per box may be more than 5,000 yuan. The original niraparib drug marketed overseas is more expensive than domestically. There are also generic niraparib drugs produced in other countries. Their pharmaceutical ingredients are basically the same as those of the original niraparib drug sold domestically and abroad. The price of 100mg*30 tablets per box produced by a Bangladesh pharmaceutical factory may be more than 1,000 yuan (the price may fluctuate due to exchange rates).